Aditxt, Inc., a biotech company, has filed a Current Report on Form 8-K with the SEC, detailing amendments to a previously announced merger agreement with Evofem Biosciences, Inc. The report, dated January 30, 2024, outlines the Second Amendment to the Merger Agreement, which includes changes to the date of the Parent Loan to Evofem and the filing date for the Joint Proxy Statement, now set for April 1, 2024. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report emphasizes that this is not a solicitation of a proxy or an offer to buy or sell securities, and that the definitive proxy statement/prospectus will be mailed to stockholders once cleared by the SEC. The document also contains forward-looking statements and urges stockholders to read the proxy statement/prospectus and other related documents carefully when they become available.

Aditxt, Inc., a biotech company, has filed a Current Report on Form 8-K with the SEC, detailing amendments to a previously announced merger agreement with Evofem Biosciences, Inc. The report, dated January 30, 2024, outlines the Second Amendment to the Merger Agreement, which includes changes to the date of the Parent Loan to Evofem and the filing date for the Joint Proxy Statement, now set for April 1, 2024. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report emphasizes that this is not a solicitation of a proxy or an offer to buy or sell securities, and that the definitive proxy statement/prospectus will be mailed to stockholders once cleared by the SEC. The document also contains forward-looking statements and urges stockholders to read the proxy statement/prospectus and other related documents carefully when they become available.